Based on a filing on October 23 in Massachusetts federal court, Roche, the Swiss pharmaceutical giant, has reached a settlement in a patent lawsuit against Biogen, which happens to be a U.S. biotech firm. The lawsuit was concerning Biogen’s biosimilar variant of Roche’s incredibly successful rheumatoid arthritis drug, Actemra. Roche, along with its affiliates, Genentech […]
Related Articles
This post first appeared on Leading Pharmaceutical Industry Online Platform, please read the originial post: here